CoChat

Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

Open access
Mileshkin, Linda R, Moore, Kathleen N, Barnes, Elizabeth H, Gebski, Val, Narayan, Kailash, King, Madeleine T, Bradshaw, Nathan, Lee, Yeh Chen, Diamante, Katrina, Fyles, Anthony W, Small, William, Gaffney, David K, Khaw, Pearly, Brooks, Susan, Thompson, J Spencer, Huh, Warner K, Mathews, Cara A, Buck, Martin, Suder, Aneta, Lad, Thomas E, Barani, Igor J, Holschneider, Christine H, Van Dyk, Sylvia, Quinn, Michael, Rischin, Danny, Monk, Bradley J, Stockler, Martin R · 2023 · The Lancet Oncology
Cited by 205

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Standard treatment for locally-advanced cervical cancer is chemo-radiation, but many patients relapse and die of distant metastatic disease. OUTBACK was designed to determine the effects on survival of adjuvant chemotherapy after chemo-radiation. Methods: OUTBACK was an international, randomised phase 3, intergroup trial. Eligible participants had locally-advanced cervical cancer (FIGO 2008 stage IB1 & node positive, IB2, II, IIIB or IVA) suitable for chemo-radiation. Participants were randomly assigned to standard cisplatin-based chemo-radiation, or standard cisplatin-based chemo-radiation followed by adjuvant chemotherapy with 4 cycles of carboplatin and paclitaxel. The primary endpoint was overall survival (OS) at 5 years. Efficacy was assessed in the intention-to-treat population (ie, all eligible patients who were randomly assigned to treatment) and safety was assessed in all participants in the control group who started chemoradiotherapy and all participants in the experimental group who received at least one dose of adjuvant chemotherapy. The study is registered on ANZCTR.org.au; ACTRN12610000732088. Findings: 919 of 926 participants recruited from April 2011 to June 2017 were eligible and included in the primary analysis: 463 assigned adjuvant chemotherapy, 456 control. Median (IQR) age was 46 (37–55) years. Ethnicity was 663 (72%). Adjuvant chemotherapy was started in 361 (78%) participants assigned it. Median follow-up was 60 months (IQR 45–65). OS at 5 years was similar among those assigned adjuvant chemotherapy versus control (105 vs 116 deaths, survival rate 72% (95%CI: 67–76%) vs 71% (95%CI: 66–75%), difference 1%, 95% CI −6 to +7; P=0·81). The hazard ratio for OS was 0·90 (95% CI 0·70–1·17). AE of grade 3–5 within a year of randomisation occurred in 81% assigned adjuvant chemotherapy versus 62% assigned control, but there were no differences in AEs beyond 1-year post randomisation. The most common clinically significant grade 3–4 adverse events were decreased neutrophils in 71 (20%) assigned adjuvant chemotherapy vs 34 (8%) control, and anaemia in 66 (18%) assigned adjuvant chemotherapy vs (34 (8%) control. Serious adverse events occurred in 107 (30%) assigned adjuvant chemotherapy versus 98 (22%) control. There were no treatment-related deaths. Patterns of disease recurrence were similar in the two groups. Interpretation: Adjuvant carboplatin and paclitaxel chemotherapy given after standard cisplatin-based chemo-radiation for unselected locally-advanced cervical cancer increased short-term toxicity but did not improve OS, so should not be given in this setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(23)00147-x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 205

Metadata

Authors
Mileshkin, L. R., Moore, K. N., Barnes, E. H., Gebski, V., Narayan, K., King, M. T., Bradshaw, N., Lee, Y. C., Diamante, K., Fyles, A. W., Small, W., Gaffney, D. K., Khaw, P., Brooks, S., Thompson, J. S., Huh, W. K., Mathews, C. A., Buck, M., Suder, A., Lad, T. E., Barani, I. J., Holschneider, C. H., Van Dyk, S., Quinn, M., Rischin, D., Monk, B. J., & Stockler, M. R.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2023-05
Volume
24
Issue
5
Pages
468-482
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4366085279
Cited by
205
References
4
FWCI
56.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00147-x
The paper
Mileshkin, L. R., Moore, K. N., Barnes, E. H., Gebski, V., Narayan, K., King, M. T., Bradshaw, N., Lee, Y. C., Diamante, K., Fyles, A. W., Small, W., Gaffney, D. K., Khaw, P., Brooks, S., Thompson, J. S., Huh, W. K., Mathews, C. A., Buck, M., Suder, A., . . . Stockler, M. R. (2023). Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00147-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.